SCHEMBL1004865

SCHEMBL1004865

Cc1cc(-c2nc(CN3CCN(C)CC3)no2)cc2c1CN(Cc1ccc(OC(F)(F)F)cc1)C2=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 2/20 0.68
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.38
HIF1A Q16665 1/20 0.37
STAT3 P40763 2/20 0.37
KCNH2 Q12809 2/20 0.37
SCN5A Q14524 2/20 0.37
SCN1A P35498 1/20 0.37
SCN4A P35499 1/20 0.37
SCN9A Q15858 1/20 0.37
SCN2A Q99250 1/20 0.37
SCN3A Q9NY46 1/20 0.37
SCN8A Q9UQD0 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37
ABL1 P00519 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
PHGDH O43175 1/20 0.36
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35
PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1003316 0.88 GRM2 (0.85) GRM2ALDH1A1TSHRHIF1ASTAT3
SCHEMBL2023554 0.81 GRM2 (0.84) GRM2ALDH1A1TSHRSTAT3KCNH2
SCHEMBL1000992 0.81 GRM2 (0.81) GRM2ALDH1A1TSHRHIF1ASTAT3
SCHEMBL2124540 0.81 GRM2 (1.00) GRM2ALDH1A1TSHRSTAT3KCNH2
SCHEMBL1005072 0.78 GRM2 (0.76) GRM2ALDH1A1STAT3KCNH2SCN5A
SCHEMBL27733525 0.78 GRM2 (0.57) GRM2ALDH1A1TSHRHIF1ASTAT3
SCHEMBL2022166 0.77 GRM2 (0.78) GRM2ALDH1A1KCNH2SCN5ASCN1A
SCHEMBL2585975 0.77 GRM2 (0.92) GRM2ALDH1A1STAT3KCNH2SCN5A
SCHEMBL16673472 0.77 GRM2 (0.74) GRM2ALDH1A1TSHRSTAT3KCNH2
SCHEMBL2025577 0.75 GRM2 (0.75) GRM2ALDH1A1TSHRKCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868008-B2 Substituted isoindolones and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-01-11 US disclosed
US-20090111830-A1 SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111830-A1 SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS GRM1, GRIN1, GRM2 GRM2 3/4885ALDH1A1 1757/4885TSHR 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.